Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001171843-25-005261
Filing Date
2025-08-11
Accepted
2025-08-11 07:01:06
Documents
62
Period of Report
2025-06-30

Document Format Files

Seq Description Document Type Size
1 FORM 10-Q cmpx20250630_10q.htm   iXBRL 10-Q 962909
2 EXHIBIT 31.1 ex_846755.htm EX-31.1 13019
3 EXHIBIT 31.2 ex_846756.htm EX-31.2 13008
4 EXHIBIT 32.1 ex_846757.htm EX-32.1 5301
5 EXHIBIT 32.2 ex_846758.htm EX-32.2 5281
  Complete submission text file 0001171843-25-005261.txt   5021591

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA cmpx-20250630.xsd EX-101.SCH 42604
7 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE cmpx-20250630_def.xml EX-101.DEF 290007
8 XBRL TAXONOMY EXTENSION LABEL LINKBASE cmpx-20250630_lab.xml EX-101.LAB 262345
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE cmpx-20250630_pre.xml EX-101.PRE 320629
10 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE cmpx-20250630_cal.xml EX-101.CAL 35017
65 EXTRACTED XBRL INSTANCE DOCUMENT cmpx20250630_10q_htm.xml XML 858572
Mailing Address 80 GUEST STREET BOSTON MA 02135
Business Address 80 GUEST STREET BOSTON MA 02135 617-500-8099
Compass Therapeutics, Inc. (Filer) CIK: 0001738021 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39696 | Film No.: 251200100
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)